13. The use according to one of claims 1 to 12, wherein the administration of said porcine circovirus type 2 antigen does not show adverse events or injection site reactions.

14. The use of a porcine circovirus type 2 antigen for the preparation of a single-dose medicament for improving the level of general disease resistance of pigs, wherein said porcine circovirus type 2 antigen is a recombinant PCV2 ORF2 protein, and wherein said medicament is administered to a pig in a single dose.

15. The use according to any one of claims 1 to 14, wherein said medicament is an immunogenic composition.

16. The use according to any one of claims 1 to 15, wherein said medicament is a vaccine.

17. Use of an immunogenic composition capable of eliciting or enhancing an immune response against porcine circovirus type 2 (PCV) and comprising recombinantly produced PCV2 ORF2 protein in the manufacture of a medicament for preventing one or more of the following symptoms associated with PCV2 infection:
nasal shedding, increased mortality rate, decreased average daily weight gain, wherein the PCV2 ORF2 protein is to be administered once to a pig.

18. The use according to claim 17, wherein the recombinantly produced PCV2 ORF2 protein is baculovirus expressed PCV2 ORF2 protein.

19. The use according to claim 17 or 18, wherein the recombinantly produced PCV2 ORF2 protein has been obtained by a method, wherein

- susceptible cells are infected with a recombinant baculovirus vector containing PCV2 ORF2 DNA coding sequences,
- PCV2 ORF2 polypeptide is expressed by the recombinant baculovirus, and
- the expressed PCV2 ORF2 polypeptide is recovered from the supernate by filtration and inactivated.

20. The use according to any one of claims 17 to 19, wherein the recombinantly produced PCV2 ORF2 protein has been recovered from the supernate of in vitro cultured cells, wherein said cells were infected with a recombinant baculovirus vector containing PCV2 ORF2 DNA and expressing PCV2 ORF2 protein, and wherein said cell cultire was treated with 2 to 8 mM binary ethylenimine (BEI) to inactivate the baculovirus vector, and an equivalent concentration of a neutralization agent.

21. The use according to any one of claims 17 to 20, the composition further comprising at least a portion of recombinant baculovirus vector expressing said PCV2 ORF2 protein.

22. The use according to claim 21, the composition further comprising a portion of cell culture supernate.

23. The use according to any one of claims 17 to 22, wherein the composition is a vaccine.

24. The use according to any one of claims 17 to 23, the composition comprising from 0.3 to 200 μg of the recombinantly produced PCV2 ORF2 protein per dose.

25. The use according to any one of claims 17 to 24, wherein the pigs are pigs of 2 weeks of age or older, but not older than 15 weeks of age.

26. The use according to any one of claims 17 to 25, wherein the composition further comprises an adjuvant.

27. The use according to claim 26, wherein the adjuvant can include aluminum hydroxide and aluminum phosphate, saponins, water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion, or wherein the adjuvant is a compound chose from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative.

28. The use according to claim 26 or 27, the composition comprising 100 μg to 10 mg of adjuvant per dose.

29. The use according to any one of claims 17 to 28, wherein the immunogenic composition is substantially free of antigens or polypeptides from PCV2 other than PCV2 ORF2 protein.

30. The use according to claim 20, wherein the immunogenic composition further comprises an adjuvant listed in claim 27 and is stable over a period of 24 months.

31. The use according to any one of claims 17 to 30, wherein the medicament is to be administered intramuscularly.